CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
BIA 9-1067 +1 moredrug
Likely dose
BIA 9-1067 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02305017
NCT02305017Phase 1Completed
CompareCT.gov

Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers

Bial - Portela C S.A.·interventional·Posted Dec 2, 2014·Updated Nov 18, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 and Paracetamol for Parkinson's Disease. Completed, enrolled 28 participants.

Detailed Summary

Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods separated by a washout period of 14 days or more.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2, 2014
Enrollment StartMar 1, 2014
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.6 years ago

Interventions

BIA 9-1067drug

BIA 9-1067 50 mg

Paracetamoldrug

Paracetamol 1g